Publications by authors named "Shelly L Schmidt"
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors.
Antoine Hollebecque Hyun C Chung Maria J de Miguel Antoine Italiano Jean-Pascal Machiels Shelly L Schmidt
Clin Cancer Res
December 2021
Article Synopsis
- - Immune checkpoint inhibitors like anti-PD-1/PD-L1 have effectiveness against MSI-H/dMMR tumors, but a significant percentage (50-60%) don’t respond, and many responders relapse quickly; this trial explored the safety and anti-tumor effects of new treatments
- - The study included 82 patients, mostly with colorectal or endometrial cancers, who received either the LY3300054 antibody alone or combined with anti-TIM-3, focusing on those who hadn’t responded to previous therapies
- - Results showed that while the treatments were generally safe, the response rates varied: 32.5% for monotherapy and 45% for the combination in treatment-naïve patients, suggesting potential